Healthcare / Drug Manufacturers - Specialty & GenericKSE
$9110.00
-160.00 (-1.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $3.7B · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$157.6B
P/E
18.0x
↓EV/EBITDA
5.6x
↓ROE
2.8%
↑Gross Margin
60.5%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.3%
FCF CAGR
—
FCF margin
-9.2%
FCF / Net income
-2.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $239.50B · net income $8.78B · FCF $-22.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $239.50B | $239.50B | $225.34B | $224.46B | $210.84B |
| Net Income | $8.78B | $8.78B | $21.25B | $22.33B | $24.31B |
| EBITDA | $36.97B | $36.97B | $32.87B | $34.68B | $37.80B |
| EPS | 507.00 | 507.00 | 1228.00 | 1291.00 | 1405.00 |
| Gross Margin | 60.5% | 60.5% | 62.7% | 62.2% | 62.2% |
| Operating Margin | 10.8% | 10.8% | 11.2% | 12.0% | 14.8% |
| Net Margin | 3.7% | 3.7% | 9.4% | 9.9% | 11.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.09 | 0.10 | 0.13 |
| Current Ratio | 1.63 | 1.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-22.01B | $-22.01B | $12.09B | $3.72B | $-4.88B |
| Returns | |||||
| ROE | 2.8% | 2.8% | 6.9% | 8.0% | 9.1% |
| Valuation | |||||
| P/E | 17.97 | 17.97 | 8.93 | 11.00 | 12.21 |
| EV/EBITDA | 5.59 | 5.59 | 6.40 | 7.81 | 8.42 |
| P/B | 0.50 | 0.50 | 0.61 | 0.88 | 1.11 |
| Growth & Yield | |||||
| Revenue Growth | 6.3% | 6.3% | 0.4% | 6.5% | — |
| EPS Growth | -58.7% | -58.7% | -4.9% | -8.1% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.8%
EPS terminal req.
$808.36
Spread vs growth
-75.5%
5Y implied EPS CAGR
14.0%
EPS terminal req.
$978.12
Spread vs growth
-72.8%
10Y implied EPS CAGR
12.0%
EPS terminal req.
$1575.27
Spread vs growth
-70.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.6%
Start / end P/E
9.1x → 18.5x
EPS bridge
1228.00 → 507.00
Residual
-60.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.